Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 75Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 59Lymphoma, Non-Hodgkin 57Hodgkin Disease 55Multiple Myeloma 54Myelodysplastic Syndromes 52Leukemia 45Lymphoma, Mantle-Cell 42Lymphoma, Follicular 39Lymphoma, Large B-Cell, Diffuse 36Lymphoma 36Lymphoma, B-Cell, Marginal Zone 35Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Myeloproliferative Disorders 32Leukemia, Myelomonocytic, Chronic 31Burkitt Lymphoma 31Congenital Abnormalities 28Lymphoma, Large-Cell, Immunoblastic 27Waldenstrom Macroglobulinemia 26Leukemia, Myeloid, Chronic-Phase 25Leukemia, Myeloid, Accelerated Phase 23Lymphoma, T-Cell, Cutaneous 21Recurrence 20Primary Myelofibrosis 20Lymphoma, Large-Cell, Anaplastic 19Dendritic Cell Sarcoma, Interdigitating 19Hematologic Neoplasms 18Blast Crisis 18Anemia, Refractory, with Excess of Blasts 18

Interventions

fludarabine phosphate 3fludarabine 2Whole-Body Irradiation 2Thiotepa 2Melphalan 2Cyclosporins 2Cyclosporine 2Antilymphocyte Serum 2Alemtuzumab 2plerixafor 1Voriconazole 1Tacrolimus 1Photopheresis 1Phlebotomy 1Mycophenolic Acid 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Cyclophosphamide 1Clofarabine 1Busulfan 1Blood Specimen Collection 1B-Cell Activating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Immunologic Deficiency Syndromes × Whole-Body Irradiation × Clear all
NCT00553098 2020-02-17

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Fred Hutchinson Cancer Center

Phase 2 Completed
29 enrolled 19 charts

Immunologic Deficiency Syndromes

NCT01049854 2018-08-21

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

New York Medical College

Phase 2 Completed
20 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Sickle Cell, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Metabolism, Inborn Errors, Histiocytosis, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡